The case for & against
Bull & Bear analysis
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) is a biopharmaceutical company focused on developing innovative T-cell immunotherapies to treat patients with rare diseases, particularly those associated with Epstein-Barr virus (EBV) and progressive forms of Multiple Sclerosis (MS). The company's lead product, TAP-Cell (EBVALO), represents a significant advancement in cell therapy, establishing Atara's role in addressing critical unmet medical needs in the oncology and neurology sectors. Atara's business trajectory reflects a considerable investment in R&D, while navigating regulatory challenges and formulating strategic partnerships to foster growth.
Bull says
- ↑TAP-Cell targets EBV+ patients with >$500M peak annual sales.
- ↑Q3 2023 cash of $102M extends runway into Q3 2025.
- ↑Pierre Fabre partnership offers $640M milestones plus tiered royalties.
- ↑Phase I data show 51.2% ORR and 18.4-month median OS.
- ↑Strong liquidity and institutional ownership enhance financial stability.
- ↑Improving momentum and manageable debt support growth prospects.
Bear says
- ↓BLA submission timing for TAP-Cell faces regulatory uncertainty.
- ↓Bayer deal termination will slash collaboration revenue materially.
- ↓Earnings yield and profitability remain deeply negative.
- ↓Adverse event in ATA-2271 raises patient safety concerns.
- ↓Negative analyst revisions and high short interest reflect skepticism.
- ↓Elevated stock volatility may deter conservative investors.
Earnings Call · Q4 2021 · Mgmt. Guidance
Transcript signals
Bull points
- TapCell is a first-in-class breakthrough therapy-designated product that addresses urgent unmet needs, as patients in secondary PTLD have no approved therapies and a very limited median life expectancy of just a few weeks to a few months.
- Momentum continues to build for this potentially game-changing product within both the medical and investor community.
- Last month, we were also pleased to announce our strategic partnership with Fujifilm Biotech Technologies to acquire our atom manufacturing facility in Fasanox for 100 million euros, which is on track for an anticipated close in April.
Bear points
- Preliminary meeting responses and discussion did not result in alignment and unexpectedly, the FDA has initially recommended ATARA conduct a clinical study with the commercial product, as they do not agree that comparability has been demonstrated.
- as a result of such preliminary feedback received from the FDA, ATARA does not currently expect to file a BLA for TAPCEL in Q2 2022.
- we are getting data in on things like cytokine profiles and cell expansion and so forth as well, but we'll be able to provide more detail on this particular patient over the course of the coming weeks.